Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China

BACKGROUND: Pharmacoeconomic information for pembrolizumab as a second-line lung cancer treatment is insufficient in China, so we aimed to assess its cost-effectiveness versus docetaxel as a second-line treatment for patients with non-small cell lung cancer (NSCLC) in China. METHODS: A partitioned s...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yafei, Chen, Wei, Zhang, Yujun, Bo, Mingming, Li, Chunyu, Zhang, Mingyu, Li, Guohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506708/
https://www.ncbi.nlm.nih.gov/pubmed/34734032
http://dx.doi.org/10.21037/atm-21-4178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506708/
https://www.ncbi.nlm.nih.gov/pubmed/34734032
http://dx.doi.org/10.21037/atm-21-4178

Ejemplares similares